Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.

Also called NCT02906709

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 184 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02906709
Other papers using this trial's data
  • A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control Diabetes, obesity & metabolism, 2021-06 DOI, PubMed 33512755, PMC8248035 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02906709. Randomized; double masking; primary purpose treatment. Start 2016-10-17 (actual); primary completion 2018-08-21 (actual). Results posted on 2019-09-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Placebo
Intervention (Biological)
Insulin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02906709
Content hash
4f9c3a686437ce3c92bde6ea5969cbfff129c5e2e3c76dfb984a22f8d4c5ca2a